Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
661 Initial results from a phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.